Results 81 to 90 of about 941,777 (314)

The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan [PDF]

During the past 20 years, the world pharmaceutical industry has experienced a dramatic increase in R&D intensity. We apply and extend a model developed by Grabowski and Vernon (2000) with a pooled data sample of the 15 publicly listed Japanese drug firms
Mahlich, Jörg C., Roediger-Schluga, Thomas   +1 more
core  

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Articulação da indústria farmacêutica brasileira com o exterior: há evidências de especialização regressiva?

Cadernos de Saúde Pública
Em caráter exploratório, o objetivo deste artigo é investigar se há indícios de especialização regressiva no padrão de comércio exterior da indústria farmacêutica brasileira, a partir da liberalização comercial dos anos 1990.
Fábio Batista Mota, José Eduardo Cassiolato, Carlos Augusto Grabois Gadelha   +2 more
doaj  

Requirement of collaboration between pharmacologists and pathologists for drug discovery research: From a viewpoint of the pharmaceutical industry

, 2022
Motowo Nakajima
openalex   +2 more sources

Alcohol and other drugs in the Australian construction industry: a pathway for safety focused cultural change [PDF]

, 2013
Background: Anecdotal evidence from the infrastructure and building sectors highlights issues of alcohol and other drugs (AODs) and its association with safety risk on construction sites.
Biggs, Herbert, Williamson, Amy
core   +1 more source

Phenotype standardization for drug-induced kidney disease. [PDF]

, 2015
Drug-induced kidney disease is a frequent cause of renal dysfunction; however, there are no standards to identify and characterize the spectrum of these disorders.
Awdishu, Linda, Cerda, Jorge, Chakaravarthi, Raj, Davenport, Andrew, Goldstein, Stuart L, Holden, Arthur L, Macedo, Etienne, Mehta, Ravindra L, Murray, Patrick T   +8 more
core   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

A novel and practical asymmetric synthesis of eptazocine hydrobromide

Beilstein Journal of Organic Chemistry, 2018
In order to prepare eptazocine hydrobromide effectively, a novel, mild and practical asymmetric process was developed starting from 1-methyl-7-methoxy-2-tetralone under the catalysis of N-(p-trifluoromethylbenzyl)cinchonidinium bromide.
Ruipeng Li, Zhenren Liu, Liang Chen, Jing Pan, Kuaile Lin, Weicheng Zhou   +5 more
doaj   +1 more source

What's Good for Washington: Fair Prescription Drug Pricing and the Biotechnology Industry [PDF]

, 2003
The rising cost of prescription drugs is consuming an ever-larger portion of limited funds for basic health care and other important services in Washington state.
Rebecca Kavoussi
core  

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source